FDA Signals Increased Scrutiny for Gummy Supplements, Citing Potency Failures
The US Food and Drug Administration (FDA) has flagged significant quality and accuracy concerns regarding gummy dietary supplements, particularly citing widespread potency failures in independent testing. This indicates impending heightened regulatory pressure and potential market shifts for manufacturers and brand owners in the category.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Washington, United States — 07 October 2026
The US Food and Drug Administration (FDA) has articulated significant concerns regarding the quality and label accuracy of dietary supplements presented in gummy formats. The agency attributes these issues to the unique formulation and manufacturing complexities inherent in gummy production, which frequently lead to products failing to meet their stated nutrient content.
FDA scientists are emphasising the critical need for scientifically rigorous production methodologies and comprehensive testing regimes to safeguard label accuracy and consumer safety. This regulatory stance is reinforced by independent testing conducted by NOW Foods, which uncovered widespread potency failures across various vitamin C gummy supplements available through online retail channels. Such findings underscore a systemic vulnerability within the gummy segment.
While the FDA has indicated it will offer guidance to industry participants aimed at process improvement, industry experts contend that substantial progress is contingent upon more stringent regulatory enforcement. This necessitates direct action against manufacturers whose products consistently fail to meet compliance standards. The current environment suggests a shift from advisory guidance to a more assertive regulatory posture.
What this means for United States
US brand owners and contract manufacturers face imminent pressure to demonstrate robust quality control and formulation stability for gummy products. Non-compliance risks significant FDA enforcement actions, including Warning Letters, import alerts, or mandatory recalls, directly impacting revenue and brand reputation. Investing now in advanced stability testing and reformulation expertise offers a competitive advantage, enabling brands to differentiate through verified potency and compliance. Retailers, including major chains like CVS and Walgreens, will likely demand stricter quality documentation from suppliers, potentially creating de-listing risks for brands unable to meet new, higher standards by early 2027.
The emphasis on robust production and testing will inevitably compress margins for manufacturers who have not yet invested in these capabilities. Procurement strategies must pivot towards high-quality, stable ingredient forms suitable for gummy matrices, necessitating renegotiations with suppliers and potential increases in raw material costs by 5-8%.
Brand owners increasingly rely on contract-manufacturing partners such as Supplement Factory to navigate these requirements.